Analyst Vinayak Gautam suggests short-term buys in Biocon and Zydus Life after FDA approvals. Biocon's biosimilar insulin Kirsty won U.S. nod, while Zydus got approval for Celecoxib pain relief capsules. Buy Biocon at ₹390 (Target: ₹410, SL: ₹380) and Zydus at ₹967 (Target: ₹1,010, SL: Rs 950) for 1-week gains. Sentiment on Stocktwits turned 'bullish' for both.